Relationship of patient background with macro- and microvascular complications: a 2-year post-marketing surveillance of vildagliptin in nearly 20,000 Japanese diabetic patients

References

• World Health Organization. Global report on diabetes [Internet]; 2016. (ISBN 978 92 4 156525 7). Available from: http://www.who.int
   Google Scholar
• Solli O, Stavem K, Kristiansen IS. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes. 2010;8:18.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al.; Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the american diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2018;41:2669–2701.
   PubMed Web of Science ®Google Scholar
• Tajima N, Noda M, Origasa H, et al. Evidence-based practice guideline for the treatment for diabetes in Japan 2013. Diabetol Int. 2015;6:151–187.
   Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Diabetes control and complications trial research group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117.
   PubMed Web of Science ®Google Scholar
• Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23:B21–29.
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group, Cushman WC, Evans GW, et al.. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–1585.
   PubMed Web of Science ®Google Scholar
• Huang D, Refaat M, Mohammedi K, et al. Macrovascular complications in patients with diabetes and prediabetes. Biomed Res Int. 2017 [cited 2017];9. DOI:10.1155/2017/7839101
   Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010;33:983–990.
   PubMed Web of Science ®Google Scholar
• Rajagopalan S. Glycemic control for macrovascular disease in type II diabetes: evidence and insights from recent trials. Am J Med. 2015;5(Suppl 1):S83–S94.
   Google Scholar
• Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:951–964.
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Araki S, Kawai K, et al. Current status of achieving blood pressure target and its clinical correlates in Japanese type 2 diabetes (JDDM45). J Diabetes Investig. 2018;9:594–601.
   Web of Science ®Google Scholar
• Haneda M, Noda M, Origasa H, et al. japanese clinical practice guideline for diabetes 2016. J Diabetes Investig. 2018;9:657–697.
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Araki S, Kawai K, et al. Declining trends of diabetic nephropathy, retinopathy and neuropathy with improving diabetes care indicators in Japanese patients with type 2 and type 1 diabetes (JDDM 46). BMJ Open Diabetes Res Care. 2018;6:e000521.
   PubMed Web of Science ®Google Scholar
• Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig. 2016;7(Suppl 1):102–109.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf. 2018;17:387–405.
   PubMed Web of Science ®Google Scholar
• Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study. Curr Med Res Opin. 2017;33:797–801.
   PubMed Web of Science ®Google Scholar
• Williams R, de Vries F, Kothny W, et al. Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study. Diabetes Obes Metab. 2017;19:1473–1478.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Barnett AH, Brath H, et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract. 2013;67:947–956.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Kozlovski P, Paldánius PM, et al. Clinical safety and tolerability of vildagliptin - insights from randomised trials, observational studies and post-marketing surveillance. Eur Endocrinol. 2017;13:68–72.
   PubMedGoogle Scholar
• Araki S, Nishio Y, Araki A, et al. Factors associated with progression of diabetic nephropathy in Japanese elderly patients with type 2 diabetes: sub-analysis of the Japanese elderly diabetes intervention trial. Geriatr Gerontol Int. 2012;12(Suppl 1):127–133.
   PubMedGoogle Scholar
• Kawasaki R, Tanaka S, Tanaka S, et al. Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan diabetes complications study (JDCS). Diabetologia. 2011;54:2288–2294.
   PubMed Web of Science ®Google Scholar
• Sone H, Tanaka S, Tanaka S, et al. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan diabetes complications study (JDCS). J Clin Endocrinol Metab. 2011;96:3448–3456.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Tanaka S, Iimuro S, et al. Predicting macro- and microvascular complications in type 2 diabetes: the Japan diabetes complications study/the Japanese elderly diabetes intervention trial risk engine. Diabetes Care. 2013;36:1193–1199.
   PubMed Web of Science ®Google Scholar
• Kikuchi M, Abe N, Kato M, et al. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;83:233–240.
   PubMed Web of Science ®Google Scholar
• Kikuchi M, Utsunomiya K, Moriya T, et al. Long-term evaluation of vildagliptin in patients with type 2 diabetes; mono or combination with sulfonylurea therapy for 52 weeks. J New Rem Clin. 2010;59:137–154.
   Google Scholar
• Equa [package insert]; 2016. (ver.14). Tokyo, Japan: Novartis Pharma K. K.
   Google Scholar
• Hirose T, Suzuki M, Tsumiyama I, et al. Efficacy and safety of vildagliptin as an add-on to insulin with or without metformin in Japanese patients with type 2 diabetes mellitus: A 12-week, double-blind, randomized study. Diabetes Ther. 2015;6:559–571.
   PubMed Web of Science ®Google Scholar
• Bramlage P, Gitt AK, Binz C, et al. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol. 2012;11:122.
   PubMed Web of Science ®Google Scholar